In conclusion, inhibition of PTGR2 is a new therapeutic approach to treat diabetes and obesity through increasing endogenous PPARγ ligands while avoiding side effects including increased adiposity, fluid retention, and osteoporosis. This evidence concerns the gene PPARG and obesity due to melanocortin 4 receptor deficiency.